Lamotrigine

When ATH:
N03AX09

Characteristic.

Powder from white to pale cream color, slightly soluble in water.

Pharmacological action.
Anticonvulsant.

Application.

Seizures: convulsive (tonico-clauniceskie), partial and generalized, Lennox-Gastaut syndrome (resistant to other antikonvulsantnym tools).

Contraindications.

Hypersensitivity, expressed human liver, hepatic failure, pregnancy, breast-feeding, childhood (to 12 years).

Pregnancy and breast-feeding.

Category actions result in FDA - C. (The study of reproduction in animals has revealed adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not held, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk.)

Side effects.

Headache, dizziness, drowsiness, sleep disorders, feeling tired, aggressiveness, confusion, nausea, liver dysfunction, lymphadenopathy, leukopenia, thrombocytopenia, skin rash, angioedema, Syndrome Stevens - Johnson, toxic skin necrosis.

Cooperation.

Other anti-convulsants (Carbamazepine, phenytoin), inducing system zitohroma P450, paracetamol eliminatiu up.

Overdose.

Symptoms: ataxia, nistagmo, dizziness, drowsiness, headache, vomiting, coma.

Treatment: gastric lavage, Activated carbon.

Dosing and Administration.

Inside, from 25-200 mg/day (to 700 mg per day); dose, frequency and duration of the admission picked individually.

Precautions.

It will be appreciated, that sudden elimination lamotrigina could trigger increases stroke, and the dose should be reduced gradually.

Cooperation

Active substance	Description of interaction
Valproic Acid	FKV. FMR. Inhibits biotransformation, increases in more than 2 times the equilibrium concentration and may increase side effects. Against the backdrop of lamotrigine reduces content in the tissues .
Haloperidol	FMR: antagonizm. Reduces sudorozhny threshold and weakens the effect.
Carbamazepine	FKV. FMR. As a CYP450 inducer accelerates the Elimination of, relaxing effect.
Clonazepam	FMR: synergism. Strengthens (mutually) CNS depression.
Paracetamol	FKV. FMR. Accelerates elimination, relaxing effect.
Prymydon	FKV. Increases clearance, shortens T1/2.
Phenytoin	FKV. FMR. As a CYP450 inducer speeds up biotransformatia and weakens the effect.
Phenobarbital	FKV. Accelerates biotransformation, increases clearance, shortens T1/2.
Chloramphenicol	FKV. FMR. Inhibits biotransformation, increases concentration in the tissues and may intensify side effects.
Ethanol	Strengthens (mutually) CNS depression; at the time of treatment should abandon admission alcohol-containing beverages.